Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)

Bibliographic Details
Title:	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)
Authors:	Garon, Edward B., Cho, Byoung Chul, Reinmuth, Niels, Lee, Ki Hyeong, Luft, Alexander, Ahn, Myung-Ju, Robinet, Gilles, Le Moulec, Sylvestre, Natale, Ronald, Schneider, Jeffrey, Shepherd, Frances A., Garassino, Marina Chiara, Geater, Sarayut Lucien, Szekely, Zsolt Papai, Van Ngoc, Tran, Liu, Feng, Scheuring, Urban, Patel, Nikunj, Peters, Solange, Rizvi, Naiyer A.
Source:	In Clinical Lung Cancer July 2021 22(4):301-312
Database:	ScienceDirect